Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

dual tasking

- PMLiVE

Eli Lilly set to launch Tempo Personalized Diabetes Management Platform

Users can use the app to log insulin doses, set reminders and access education resources

- PMLiVE

Creating the urgency and drive needed to tackle antimicrobial resistance

By Jamie Doggett

- PMLiVE

Pfizer’s multiple myeloma treatment granted FDA Breakthrough Therapy Designation

Elranatamab-treated patients achieved an overall response rate of 61% in a phase 2 trial

- PMLiVE

Lab-grown red blood cells used for human transfusions in world-first clinical trial

Manufactured blood cells could revolutionise treatments for people with blood disorders

- PMLiVE

Ionis reports positive phase 2b results for fesomersen in thrombosis prevention

The company also announced it will regain rights to the antisense medicine from Bayer

- PMLiVE

Sandoz to invest €50m in Austrian manufacturing facility to meet global antibiotic demand

Amoxicillin and other vital penicillin products will benefit from the investment

- PMLiVE

Boehringer and Lilly’s Jardiance shows promise in phase 3 chronic kidney disease trial

Jardiance reduced disease progression and cardiovascular death by 28%

- PMLiVE

Sorted Communications appoints Harry Loney and Lorna Walkden as communications managers

Both Loney and Walkden have over 35 years’ experience in marketing and communication

https://youtu.be/DHVko7tyOPo

Health content that resonates

Here at Thrive, our purpose is to help everyone to better health through content that informs and empowers them.Since 2001 our researchers, writers, medical and behavioural experts have been on...

Thrive Agency

- PMLiVE

GSK to submit drug application for new antibiotic to US FDA

Gepotidacin could be the first new novel oral antibiotic treatment for uncomplicated urinary tract infections in over 20 years

- PMLiVE

Pfizer and BioNTech dose first patient in COVID-19/flu combination vaccine study

The vaccine aims to protect individuals against two severe respiratory viral diseases

- PMLiVE

AstraZeneca/Sanofi’s Beyfortus receives EC approval for prevention of RSV in infants

The decision makes the antibody the first broadly protective option for this age population

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links